{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Defined as the percentage of participants having CR, PR, or stable disease (SD) based on investigator assessment per RECIST v1.1.","groups":[{"description":"INCAGN01876 in combination with pembrolizumab and epacadostat","id":"OG000","title":"INCAGN01876 + Pembrolizumab + Epacadostat"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The FAS includes all participants enrolled in the study who received at least 1 dose of INCAGN01876, pembrolizumab, or epacadostat.","reportingStatus":"POSTED","timeFrame":"Assessed every 9 weeks for 12 months, then every 12 weeks, up to 18 months.","title":"Phase 1 & Phase 2: Disease Control Rate Based on RECIST v1.1 and mRECIST","type":"SECONDARY","unitOfMeasure":"Participants"}